Equity Overview
Price & Market Data
Price: $14.87
Daily Change: +$0.42 / 2.82%
Range: $14.27 - $14.93
Market Cap: $1,746,351,360
Volume: 1,531,538
Performance Metrics
1 Week: 13.58%
1 Month: -13.97%
3 Months: 8.24%
6 Months: 77.14%
1 Year: 64.65%
YTD: 5.67%
Company Details
Employees: 342
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.